Cargando…

Risk of COVID‐19 in Patients with Cancer Receiving Immune Checkpoint Inhibitors

OBJECTIVE: The aim of this study was to determine the rate of coronavirus disease‐19 (COVID‐19) among patients with cancer treated with immune checkpoint inhibitors (ICIs). MATERIALS AND METHODS: This was a retrospective study of 1,545 patients with cancer treated with ICIs between July 1, 2019, and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Klebanov, Nikolai, Pahalyants, Vartan, Murphy, William S., Theodosakis, Nicholas, Zubiri, Leyre, Klevens, R. Monina, Kwatra, Shawn G., Lilly, Evelyn, Reynolds, Kerry L., Semenov, Yevgeniy R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2021
Materias:	Brief Communications
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8100539/ https://www.ncbi.nlm.nih.gov/pubmed/33783099 http://dx.doi.org/10.1002/onco.13768

Ejemplares similares

28552 Risk of COVID-19 and subsequent mortality among patients receiving immunosuppressive biologic therapy: A retrospective matched cohort study
por: Pahalyants, Vartan, et al.
Publicado: (2021)

28630 Use of systemic immunosuppressive treatment is not related to COVID-19 positivity in a retrospective review of patients in Massachusetts
por: Murphy, William, et al.
Publicado: (2021)

Reply to: “COVID-19 vaccination in IMID patients receiving rituximab: A personalized regimen should be formulated”
por: Pahalyants, Vartan, et al.
Publicado: (2022)

27147 Antimalarials as pre-exposure prophylaxis for COVID-19: A retrospective matched cohort study
por: Klebanov, Nikolai, et al.
Publicado: (2021)

Immunosuppressive biologics did not increase the risk of COVID-19 or subsequent mortality: A retrospective matched cohort study from Massachusetts
por: Pahalyants, Vartan, et al.
Publicado: (2022)

Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA
por: Kalinich, Mark, et al.
Publicado: (2021)

336 Risks of COVID-19 infection and mortality for patients on biologics
por: Pahalyants, V., et al.
Publicado: (2021)

028 Use of systemic immunosuppressive treatment is not related to COVID-19 infection in a retrospective review of patients in Massachusetts
por: Murphy, W., et al.
Publicado: (2021)

Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study
por: Tiu, Bruce C, et al.
Publicado: (2022)

Case Report: Fulminant Celiac Disease With Combination Immune Checkpoint Therapy
por: Falade, Ayo S., et al.
Publicado: (2022)

28561 The impact of telemedicine on the delivery of dermatologic care during the COVID-19 pandemic
por: Pahalyants, Vartan, et al.
Publicado: (2021)

Massachusetts flu vaccination and application for COVID-19 routine vaccination planning
por: Hatch, Megan, et al.
Publicado: (2022)

Diagnostic utility of CT for suspected immune checkpoint inhibitor enterocolitis
por: Durbin, Sienna M, et al.
Publicado: (2020)

Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer
por: Zubiri, Leyre, et al.
Publicado: (2021)

Colitis after checkpoint blockade: A retrospective cohort study of melanoma patients requiring admission for symptom control
por: Hughes, Michael S., et al.
Publicado: (2019)

Surveillance and Seroepidemiology
por: Jiles, Ruth, et al.
Publicado: (2014)

Change in Hepatitis A Seroprevalence among U.S. Children and Adolescents: Results from the National Health and Nutrition Examination Survey 2003–2006 and 2007–2010
por: Kruszon-Moran, Deanna, et al.
Publicado: (2013)

Vital Signs: Evaluation of Hepatitis C Virus Infection Testing and Reporting — Eight U.S. Sites, 2005–2011
por: Bornschlegel, Katherine, et al.
Publicado: (2013)

283. Population-Based Co-infection of Carbapenem-Resistant Organisms and SARS-CoV-2 in Massachusetts
por: Geoghegan, Ashley, et al.
Publicado: (2021)

Identification of cutaneous immune-related adverse events by International Classification of Diseases codes and medication administration
por: Chen, Wenxin, et al.
Publicado: (2022)

Prevalence of inverse psoriasis subtype with immune checkpoint inhibitors
por: Jfri, Abdulhadi, et al.
Publicado: (2022)

Pericardial disease in patients treated with immune checkpoint inhibitors
por: Gong, Jingyi, et al.
Publicado: (2021)

Incidence of Active Tuberculosis in Lung Cancer Patients Receiving Immune Checkpoint Inhibitors
por: Fujita, Kohei, et al.
Publicado: (2020)

Rosacea and Rate of Temperature Change: Examining Real-Time Data from 2004 to 2016
por: He, Alice, et al.
Publicado: (2018)

Rapidly progressive squamous cell carcinoma in a patient with longstanding history of folliculitis decalvans
por: Pahalyants, Vartan, et al.
Publicado: (2021)

Clinical Presentations and Outcomes of Patients Receiving Immune Checkpoint Inhibitors Presenting to the Emergency Department
por: Castillo, Richmond M., et al.
Publicado: (2021)

1151 Geographic Distances Between Patients and Providers for Hepatitis C Virus Infection Testing
por: Klevens, Monina, et al.
Publicado: (2014)

Renin–angiotensin–aldosterone system inhibitors and survival in patients with hypertension treated with immune checkpoint inhibitors
por: Drobni, Zsofia D., et al.
Publicado: (2022)

Syndrome Development to Assess IDU, HIV, and Homelessness in MA Emergency Departments
por: Albert, Stefanie P., et al.
Publicado: (2019)

Proteomic and Phosphoproteomic Analysis Reveals that Neurokinin-1 Receptor (NK1R) Blockade with Aprepitant in Human Keratinocytes Activates a Distinct Subdomain of EGFR Signaling: Implications for the Anti-Pruritic Activity of NK1R Antagonists
por: Kwatra, Shawn G., et al.
Publicado: (2019)

The Massachusetts Hepatitis C Testing Cascade, 2014-2016
por: Vo, Quynh T, et al.
Publicado: (2019)

Association between Itch and Cancer in 3836 Pediatric Pruritus Patients at a Tertiary Care Center
por: Belzberg, Micah, et al.
Publicado: (2019)

Decreased Absolute Lymphocyte Count and Increased Neutrophil/Lymphocyte Ratio With Immune Checkpoint Inhibitor–Associated Myocarditis
por: Drobni, Zsofia D., et al.
Publicado: (2020)

The Use of the International Classification of Diseases, Ninth Revision (ICD-9) Coding in Identifying Chronic Hepatitis B Virus Infection in Health System Data: Implications for Surveillance
por: Mahajan, Reena, et al.
Publicado: (2013)

Digital health evaluation workshop for interprofessional healthcare students
por: Aungst, Timothy Dy, et al.
Publicado: (2017)

Association between incidental statin use and skeletal myopathies in patients treated with immune checkpoint inhibitors
por: Drobni, Zsofia D, et al.
Publicado: (2021)

Outpatient Antibiotic Prescribing in Massachusetts, 2011–2015
por: Klevens, R Monina, et al.
Publicado: (2019)

Surveillance for Hepatitis C
por: Ly, Kathleen N., et al.
Publicado: (2015)

Comorbidities Associated with Granuloma Annulare: A Cross-Sectional, Case-Control Study
por: Almazan, Erik, et al.
Publicado: (2020)

Somatic mutations reveal hyperactive Notch signaling and racial disparities in prurigo nodularis
por: Rajeh, Ahmad, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7pacgjmuk7svfeuj7fqnn1pq97